Advertisement

Advertisement

MAIA Stock Latest News

MAIA Biotechnology files $150M mixed securities shelf

The FlyMAIA Biotechnology files $150M mixed securities shelf

MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion

PremiumThe Fly

MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion

2M ago

MAIA Biotechnology opens third clinical site in U.S. for Phase 2 THIO-101 trial

PremiumThe Fly

MAIA Biotechnology opens third clinical site in U.S. for Phase 2 THIO-101 trial

2M ago

MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial

PremiumThe Fly

MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial

3M ago

MAIA Biotechnology receives FDA clearance for amendment to IND application

PremiumThe Fly

MAIA Biotechnology receives FDA clearance for amendment to IND application

3M ago

MAIA Biotechnology announces open market purchases by CEO, director

PremiumThe FlyMAIA Biotechnology announces open market purchases by CEO, director

3M ago

MAIA Biotechnology Shareholders Back Board and Auditor Appointments

Company Announcements

MAIA Biotechnology Shareholders Back Board and Auditor Appointments

3M ago

MAIA Biotechnology Ends ATM Stock Offering Agreement

Company Announcements

MAIA Biotechnology Ends ATM Stock Offering Agreement

3M ago

MAIA Expands THIO-101 Lung Cancer Trial in U.S.

PremiumCompany Announcements

MAIA Expands THIO-101 Lung Cancer Trial in U.S.

4M ago

MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial

PremiumCompany Announcements

MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial

5M ago

MAIA Biotechnology secures funding for clinical trial of ateganosine

PremiumThe Fly

MAIA Biotechnology secures funding for clinical trial of ateganosine

5M ago

MAIA Biotechnology Awards Executive Bonuses After Successful Financing

PremiumCompany Announcements

MAIA Biotechnology Awards Executive Bonuses After Successful Financing

5M ago

MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes

PremiumCompany AnnouncementsMAIA Highlights Promising Phase 2 NSCLC Survival Outcomes

5M ago

MAIA Showcases THIO-101 NSCLC Data at ELCC 2026

Company Announcements

MAIA Showcases THIO-101 NSCLC Data at ELCC 2026

5M ago

MAIA Biotechnology Completes $30 Million Public Stock Offering

Company Announcements

MAIA Biotechnology Completes $30 Million Public Stock Offering

6M ago

MAIA Biotechnology 20M share Spot Secondary priced at $1.50

PremiumThe Fly

MAIA Biotechnology 20M share Spot Secondary priced at $1.50

6M ago

MAIA Biotechnology announces common stock offering, no amount given

PremiumThe Fly

MAIA Biotechnology announces common stock offering, no amount given

6M ago

MAIA Biotechnology Highlights Progress in Phase 3 Oncology Program

PremiumCompany Announcements

MAIA Biotechnology Highlights Progress in Phase 3 Oncology Program

6M ago

MAIA Biotechnology published a 2026 Letter to Shareholders

PremiumThe Fly

MAIA Biotechnology published a 2026 Letter to Shareholders

6M ago

MAIA Biotechnology outlines 2026 goals for ateganosine program

PremiumCompany AnnouncementsMAIA Biotechnology outlines 2026 goals for ateganosine program

7M ago

MAIA Biotechnology highlights milestones, catalysts for FY26

The Fly

MAIA Biotechnology highlights milestones, catalysts for FY26

7M ago

MAIA Biotechnology Highlights Strategy in New Investor Presentation

Company Announcements

MAIA Biotechnology Highlights Strategy in New Investor Presentation

7M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >